US Patent Issued to Regents of the University of Minnesota on June 10 for "Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer" (Minnesota Inventors)

ALEXANDRIA, Va., June 18 -- United States Patent no. 12,325,879, issued on June 10, was assigned to Regents of the University of Minnesota (Minneapolis).

"Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer" was invented by Konstantinos Aliferis (Minneapolis), Boris Jan Nils Winterhoff (Minneapolis), Sisi Ma (Minneapolis) and Jinhua Wang (Edina, Minn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure describes methods of predicting the response of a patient with ovarian cancer to platinum-based chemotherapy and/or treatment with bevacizumab using clinical and molecular tumor characteristics in patients, methods of treating patie...